



Sept 28, 2007

U.S. Securities and Exchange Commission  
Division of Corporation Finance  
Office of International Corporate Finance  
100 F Street N.E., Mail Stop 3628  
Washington, DC 20549  
Phone: 202 551 3450

RECEIVED  
2007 OCT -4 A 8 27  
OFFICE OF INTERNATIONAL  
CORPORATE FINANCE



**SUPL**

Re: Diamyd Medical AB  
File No. 82-34956  
Documents Furnished Pursuant to Rule 12g3-2(b)

Ladies and Gentlemen:

We hereby submit, pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934, as Amended, the enclosed press release of Diamyd Medical AB:

Press Release dated as of Sept 28, 2007: **"CEO INCREASES HOLDING IN DIAMYD MEDICAL WITH 10,000 SHARES"**

Kindly acknowledge receipt of the enclosed material by stamping the copy of this letter and returning it in the self-addressed stamped envelope provided.

Very truly yours,

A handwritten signature in black ink, appearing to read "Michael Christini".

Michael A. Christini

Enclosure  
cc: Cecilia Driving

**PROCESSED**

**OCT 16 2007**

**THOMSON  
FINANCIAL**

A large, stylized handwritten signature in black ink, possibly reading "Jew 10/4".



## CEO INCREASES HOLDING IN DIAMYD MEDICAL WITH 10,000 SHARES

**Press Release, Stockholm, Sweden, September 28, 2007 – Diamyd Medical AB**  
([www.omxgroup.com](http://www.omxgroup.com), ticker: DIAM B; [www.otcqx.com](http://www.otcqx.com), ticker DMYDY)

Diamyd Medical announces that its president and CEO, Anders Essen-Moller, has increased his holdings in Diamyd Medical with 10,000 shares series B. The increase includes simultaneous exercise of 30,000 options financed through sale of 20,000 shares less tax, resulting in an increase of Diamyd Medical's cash position with SEK 1,5 million.

### About Diamyd Medical

Diamyd Medical is a life science company developing treatments for diabetes and its complications. The company's furthest developed project is the GAD-based drug Diamyd® for autoimmune diabetes for which Phase III studies are planned to be initiated this year. Diamyd® has demonstrated significant and positive results in Phase II clinical trials in Sweden.

GAD65, a major autoantigen in autoimmune diabetes, is the active substance in Diamyd. GAD65 is also an enzyme that converts the excitatory neurotransmitter glutamate to the inhibitory transmitter GABA. In this context, GAD may have an important role not only in diabetes but also in several central nervous system-related diseases. Diamyd Medical has an exclusive worldwide license from the University of California at Los Angeles regarding the therapeutic use of the GAD65 gene.

Diamyd Medical has sublicensed its UCLA GAD Composition of Matter license to Neurologix, Inc. in Fort Lee, New Jersey for treatment of Parkinson's disease with an AAV-vector.

Other projects comprise drug development within therapeutic gene transfer using the exclusively licensed and patent protected Nerve Targeted Drug Delivery System (NTDDS). The company's lead NTDDS projects include using enkephalin and GAD for chronic pain, e.g., diabetes pain or cancer pain. All projects in this field are currently in preclinical phases.

Diamyd Medical has offices in Stockholm, Sweden and Pittsburgh, PA. The Diamyd Medical share is quoted on the Stockholm Nordic Exchange in Sweden (NOMX ticker: DIAM B) and on the OTCQX-list in the United States (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). Further information is available at [www.diamyd.com](http://www.diamyd.com).

For further information, please contact:

#### Stockholm office

Anders Essen-Möller  
CEO and President  
+46 8 661 0026  
[investor.relations@diamyd.com](mailto:investor.relations@diamyd.com)

#### Pittsburgh office

Michael Christini  
President  
+1 412 770 1310  
[Michael.Christini@diamyd.com](mailto:Michael.Christini@diamyd.com)

**Diamyd Medical AB (publ). Linnégatan 89 B, SE-115 23 Stockholm, Sweden. Tel: +46 8 661 00 26, fax: +46 8 661 63 68 or E-mail: [info@diamyd.com](mailto:info@diamyd.com). VATno: SE556530-142001.**

*Disclaimer: This document contains certain "statements" relating to present understandings, future events and future performance, including statements relating to the progress, timing and completion of our research, development and clinical trials; our ability to market, commercialize and achieve market acceptance for product candidates; and our current and future strategic partner relationships. These statements can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Diamyd Medical undertakes no obligation to publicly update such statements, whether because of new information, future events or otherwise, nor does Diamyd Medical give any guarantees that the statements, given or implied, are correct. This document is a translation from the Swedish original. No guarantees are made that the translation is free from errors.*

END